All IAM Covid-19 coverage to be free to view
As of today, IAM will be putting all its coverage relating to Covid-19 and the coronavirus in front of our paywall, so making it free to view. This applies to all future stories as well as to our back catalogue of pieces. You can see the features we have run so far via these links:
Ericsson CEO strikes optimistic tone, but wireless industry waits to feel full effects of covid-19
How covid-19 is impacting US district courts and the PTAB
Covid-19 emergency may expose compulsory licensing limits
In the fight against the coronavirus outbreak, life sciences companies need certainty in 101
Donation is no defence to patent infringement in China
The danger COVID-19 presents to biopharma patent owners
Hytera: TRO in Motorola trade secrets case could hamper coronavirus response
Top Chinese official stresses need for strong pharma patents amidst Covid-19 outbreak
The impact of Covid-19 will be felt across the global IP market
Gilead downplays Chinese lab’s coronavirus patent
Wuhan lab says it will seek patent protection of Gilead antiviral
Our sister platforms World Trademark Review and Global Data Review will also be doing the same. To find relevant content for these sites, go to their home pages and use the search function.